EEG hardware that reaches the scalp through every hair type, so brain research and diagnosis include everyone.
No one should be left out of neuroscience because of their hair.
The reason Synaptive existsFor decades EEG has worked best on fine, straight hair and poorly on textured hair. That gap shows up as missing diagnoses in clinics and missing people in research.
Three researchers, same frustration: every EEG experiment we run, we watch participants excluded because of their hair.
Between us: neuroengineering, clinical research and materials science. We were told this might not work.
The people who do the work with us. Most are still studying. None of them are here to fetch coffee.
I wanted to join Synaptive because of their mission to build EEG hardware that worked for every hair type. This directly aligned with my interest in neurotechnology and inclusive brain research. I was excited by the chance to contribute to a research-led team that is solving a real-world obstacle in the clinical and neuroscience field.Chongyang Lu
I wanted to join Synaptive because it brings together my interests in neuroscience, innovation, and translating scientific research into meaningful real-world impact. With a background in neuroscience research, I recognise the importance of making scientific tools more accessible and inclusive. Synaptive’s mission to address a longstanding barrier in EEG research particularly resonated with me.Valentini Yioti
Systematic exclusion of afro-textured hair from EEG research, documented through a literature review and a survey of 55 researchers, technicians and patients.
Three disciplines, through the UCL Hatchery incubator and the Impulse programme at the Maxwell Centre, Cambridge.
Accepted at the Graz BCI Conference, supported by the EEG101 COST grant, and invited to lead a session on inclusive EEG hardware.
Recognised, and awarded £6,000, for the social impact of the work.
Selected onto Imperial's Venture Catalyst Challenge, its flagship venture-building programme.
Application 2615593.7 pending. Research edition going out to early-adopter labs, with manufacturing and internal testing running alongside.
Selected as one of a handful of ventures to pitch at London Demo Day 2026.
To scale manufacturing and take the clinical edition through certification.
Class I CE and UKCA marking, an FDA Class II pathway, then licensing and clinical adoption. Long term: NHS partnerships.
Merlin pitching Syn-R1 at London Demo Day 2026, one of a handful of ventures selected to present.









No open roles today, but we keep a list.